Characteristics and study eligibility of British lung cancer patients for clinical trials evaluating targeted therapies (TTS) or immune checkpoint inhibitors (ICIS)
Publication date
2020-10
Authors
van Veelen, Ard
Abtahi, Shahab
Souverein, Patrick C.
Driessen, Johanna H.M.
Klungel, Olaf H.
Dingemans, Anne-Marie
van Geel, Robin
De Vries, F.
Croes, Sander
Editors
Advisors
Supervisors
Document Type
Abstract
Metadata
Show full item recordCollections
License
taverne
Abstract
Keywords
Taverne, SDG 3 - Good Health and Well-being
Citation
van Veelen, A, Abtahi, S, Souverein, P, Driessen, J H M, Klungel, O H, Dingemans, A-M, van Geel, R, de Vries, F & Croes, S 2020, 'Characteristics and study eligibility of British lung cancer patients for clinical trials evaluating targeted therapies (TTS) or immune checkpoint inhibitors (ICIS)', Pharmacoepidemiology and Drug Safety, vol. 29, no. suppl. 3, 4663, pp. 46. https://doi.org/10.1002/pds.5113-2